Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own0.80% Shs Outstand280.63M Perf Week-4.24%
Market Cap6.09B Forward P/E241.00 EPS next Y0.09 Insider Trans-28.45% Shs Float260.59M Perf Month17.69%
Income-149.00M PEG- EPS next Q-0.01 Inst Own82.90% Short Float6.06% Perf Quarter33.48%
Sales123.80M P/S49.17 EPS this Y41.30% Inst Trans7.72% Short Ratio2.91 Perf Half Y99.54%
Book/sh0.12 P/B180.75 EPS next Y120.50% ROA-36.00% Target Price20.50 Perf Year467.80%
Cash/sh1.14 P/C19.04 EPS next 5Y- ROE160.90% 52W Range3.55 - 23.49 Perf YTD45.47%
Dividend- P/FCF22.08 EPS past 5Y0.90% ROI-43.80% 52W High-7.66% Beta1.87
Dividend %- Quick Ratio2.10 Sales past 5Y-27.50% Gross Margin95.40% 52W Low510.99% ATR0.89
Employees115 Current Ratio2.10 Sales Q/Q528.30% Oper. Margin- RSI (14)60.20 Volatility3.76% 4.92%
OptionableYes Debt/Eq5.97 EPS Q/Q79.00% Profit Margin- Rel Volume0.83 Prev Close21.74
ShortableYes LT Debt/Eq2.55 EarningsFeb 27 AMC Payout- Avg Volume5.43M Price21.69
Recom1.50 SMA204.11% SMA5018.06% SMA20070.44% Volume4,524,023 Change-0.23%
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
08:38AM  Why Earnings Season Could Be Great for Exelixis (EXEL)
07:49AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
Feb-23-17 04:43PM  Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
04:23PM  Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
04:16PM  ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
09:45AM  TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
Feb-22-17 03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
08:16AM  Can Penumbra (PEN) Spring a Surprise this Earnings Season?
Feb-21-17 08:46AM  Patterson Companies (PDCO) Q3 Earnings: What's in Store?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
05:15AM  Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Feb-17-17 05:02PM  Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
02:30PM  Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
09:30AM  Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis Accesswire
Feb-15-17 02:44PM  Two Great Stock Ideas in the IBB Biotech ETF at Investopedia
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-10-17 09:42AM  Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
09:30AM  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
04:10AM  Exelixis (EXEL) Shares March Higher, Can It Continue?
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
10:15AM  Ecolab (ECL): What's in the Cards this Earnings Season?
09:27AM  Buy 4 Stocks Riding High on Superb Earnings Acceleration
07:39AM  5 Drug Stocks Poised to Beat Earnings Estimates in Q4
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.06%
01:49PM  Four Biotech Stocks Breaking Out at Forbes
10:10AM  DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 Business Wire
03:26PM  5 Great Biotech Stocks to Buy Now
07:41AM  4 Drug Stocks that are Broker Favorites
Feb-03-17 11:17AM  Hopes for Tax Reform, Less Regulation Lift Indices +8.40%
Feb-02-17 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 Business Wire
07:37AM  2 Big Reasons Exelixis, Inc. Soared 22% in January at Motley Fool
Feb-01-17 08:15AM  Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Accesswire
Jan-31-17 04:05PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
11:24AM  Exelixis, Takeda Sign Japanese Cancer Drug Deal at Investopedia
07:00AM  Exelixis Inks Partnership with Takeda for Cabometyx in Japan
Jan-30-17 06:00PM  Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Business Wire
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 09:45AM  Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Accesswire
Jan-23-17 05:27PM  Better Buy: Exelixis, Inc. vs. Novartis at Motley Fool
Jan-11-17 10:49AM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : January 11, 2017
Jan-10-17 12:21PM  After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next at Motley Fool +7.57%
09:27AM  4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
09:20AM  Genentech Withdraws Cost Claims Against Exelixis at Investopedia
07:23AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017
Jan-09-17 04:14PM  Why Exelixis, Inc. Stock Zoomed Higher Today at Motley Fool +14.75%
07:25AM  3 Stocks Expected to More Than Double Their Earnings in 2017 at Motley Fool
05:13AM  Update on Dispute between Exelixis and Genentech, a Member of the Roche Group Business Wire
Jan-05-17 09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
Jan-04-17 09:15AM  Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis Accesswire
08:49AM  How calls are looking for Exelixis rally
07:24AM  Is It Too Late to Buy Exelixis Stock? at Motley Fool
Jan-03-17 06:07PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
02:04PM  ETFs with exposure to Exelixis, Inc. : January 3, 2017
10:08AM  Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year at Motley Fool
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
08:25AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016
Dec-29-16 05:29PM  4 Biotech Stocks with Bright Prospects in 2017
Dec-28-16 07:23AM  The 3 Biggest Risks for Pfizer in 2017 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-23-16 09:30AM  The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
Dec-22-16 06:18PM  Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx -8.46%
09:28AM  4 Biotech Stocks that More than Doubled in 2016
Dec-21-16 06:06AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
01:22AM  Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead? at Motley Fool
01:00AM  Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada Business Wire
01:00AM  Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada Business Wire
Dec-19-16 02:06PM  Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead at Motley Fool
09:28AM  7 Top Stocks We're Excited About Headed Into 2017 at Motley Fool
09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-14-16 01:02PM  ETFs with exposure to Exelixis, Inc. : December 14, 2016
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
Dec-13-16 01:19PM  Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite at Motley Fool
08:09AM  3 Great Stocks to Beat the Biotech Blues
Dec-12-16 09:03AM  2 Companies I Wish I'd Bought in 2016 at Motley Fool
Dec-07-16 08:38AM  Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? -8.99%
08:00AM  Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline Business Wire
Dec-05-16 06:11PM  This Dynamic Duo of Catalysts Sent Exelixis, Inc. Higher by 60% in November at Motley Fool
03:15AM  Hedge Funds Arent Crazy About John Bean Technologies Corp (JBT) Anymore at Insider Monkey
Dec-02-16 01:03PM  Why Exelixis Was a Top Stock in 2016 So Far at Motley Fool +5.15%
09:21AM  3 Biotech Stocks to Buy in December at Motley Fool
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November
11:08AM  Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions
Nov-30-16 07:43PM  5 Stocks Up 100% or More This Year at Motley Fool
05:36PM  Is Wright Medical Group Inc (WMGI) a Good Stock for Your Portfolio? at Insider Monkey
04:41PM  What's Pfizer's Excuse for Not Buying Exelixis? at Motley Fool
04:15PM  Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14 Business Wire
10:40AM  Hedge Funds Are Buying RealPage, Inc. (RP) at Insider Monkey
10:02AM  The 5 Best Biotech Stocks of 2016 at Motley Fool
09:46AM  Should You Buy Exelixis, Inc. (EXEL)? at Insider Monkey
Nov-29-16 01:52PM  Shark Bites: Eager Buyers Pounce on Pullback
Nov-28-16 07:32PM  3 Healthcare Stocks Investors Have Been Thankful for This Year at Motley Fool
Nov-24-16 05:48PM  The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3 at Insider Monkey
Nov-23-16 09:30AM  4 stocks to watch at MarketWatch
Nov-22-16 05:09PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -5.36%
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM